by
Gus Iversen, Editor in Chief | February 06, 2026
Medtronic plans to acquire CathWorks, a privately held medical device company focused on coronary physiology, building on a strategic partnership the companies formed in 2022.
The Galway, Ireland-based medtech company said it will exercise its option to purchase CathWorks for up to $585 million, with additional undisclosed earn-out payments tied to post-acquisition milestones.
The two companies have worked together since 2022 under a copromotion agreement for the CathWorks FFRangio system in the U.S., Europe and Japan, where the technology is commercially available. Medtronic said the acquisition is intended to strengthen its interventional cardiology portfolio within its cardiovascular business.
Ad Statistics
Times Displayed: 5266
Times Visited: 18 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
CathWorks’ core product, the FFRangio system, is designed to assess the physiological significance of coronary artery disease using data derived from routine coronary angiograms. Fractional flow reserve, or FFR, is widely used to help determine whether coronary lesions are causing ischemia and whether patients are likely to benefit from revascularization. While supported by clinical evidence, traditional wire-based FFR has seen limited adoption, in part due to the need for pressure wires and pharmacologic hyperemia.
According to Medtronic, FFRangio uses computational modeling and artificial intelligence to generate FFR values across the coronary tree without the use of pressure wires. The company cited published studies comparing angiography-derived FFR approaches with wire-based FFR, though it did not disclose new clinical data as part of the acquisition announcement.
Ramin Mousavi, president and chief executive officer of CathWorks, said the transaction would allow the company’s technology to reach a broader global market through Medtronic’s commercial infrastructure. CathWorks is based in Kfar Saba, Israel.
The transaction is subject to review by the U.S. Federal Trade Commission and other customary regulatory approvals. Medtronic expects the process to be completed by the end of its fiscal year 2026. Until closing, the two companies will continue to operate independently.
Medtronic said the acquisition is expected to be immaterial to its fiscal year 2027 GAAP and adjusted earnings per share, and neutral to accretive in subsequent years.
